
# Better and equitable evidence and translation for people with chronic kidney disease



#### **Jonathan Craig**

I want to acknowledge the countless patients, caregivers, clinical and research colleagues who have generously imparted their wisdom on their lived experience, and how research can truly be transformational for people with CKD



## Na Marni (welcome)

We acknowledge the traditional owners of the lands Flinders University teaches and researches across (Arrernte, Boandik, Dagoman, Erawirung, Jawoyn, Kaurna, Larrakia, Ngarrindjeri, Ngadjuri, Peramangk, Ramindjeri, Waramungu, Wardaman and Yolngu) and honour their Elders past and present. "Always was... always will be"

Image: Long Way Home - A celebration of 21 years of Yunggorendi First Nations Centre (2011)

# Outline



# Epidemiology and impact of CKD



Evidence ecosystem in CKD



## **Opportunities and challenges**




# By the numbers

CKD 10% of Australians



## Dialysis and Kidney Transplantation in Australia 2020 Summary







Source: ANZDATA. The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) collects information about people receiving dialysis or kidney transplant for end-stage kidney disease in Australia and New Zealand.

## And the experience...

Mortality 15% per year

Dialysis 3x/week for 4-5 hours leaving people washed out

Management and not cure

Unemployment, social isolation, pervasive impacts upon caregivers and family members

Uncertainty, complications and hospitalisations

Utility values of 0.6



Being alive, is important. Most of us don't like it. It's sad. You have to experience surgeries, doctors, and other medical related things. You have to experience pain, one of us feels sick, most of us feel worried, scared. Life participation is most important because without it, you can't do anything.





## THE INVERSE CARE LAW

#### JULIAN TUDOR HART

Glyncorrwg Health Centre, Port Talbot, Glamorgan, Wales

Summary The availability of good medical care tends to vary inversely with the need for it in the population served. This inverse care law

CKD, like all chronic conditions, is a disease of inequity. Some groups are

- more likely to get CKD, and progress faster
  - less likely to receive appropriate care
- less likely to be engaged in transformative research



The Lancet · Saturday 27 February 1971

## **Dimensions of inequity in CKD** PROGRESS framework

## First Nations peoples

- Risk of kidney failure 10-15x/higher in 40-60 year old people
- ¼ likelihood of receiving a transplant (12% vs 45%)

#### Rural and remote

 Less likely to receive specialist care, out of pocket expenses greater, higher mortality and hospitalization

#### Women

 2.5x more likely to be a living donor, ½ likelihood of receiving a kidney



# Outline






Evidence ecosystem in CKD




## **Opportunities and challenges**







#### Registry trials (BEST Fluids)



Systematic reviews informing RCTs

CARING FOR AUSTRALIANS & NEW ZEALANDERS WITH KIDNEY IMPAIRMENT

AUSTRALIA & NEW ZEALAND

Living guidelines (diabetes, cardiovascular disease)





# Outline





Evidence ecosystem in CKD



## **Opportunities and challenges**



## The "glue/fix" in the evidence ecosystem

– consumer voices



Shared membership of advisory groups





# Trials in haemodialysis


139 different measures for phosphate



Trials that don't address problems of relevance to end-users of research cannot inform decisions.

**362 trials**: 20% trials report mortality; 12% report CVD, 9% report






"You could have half a dozen measurements that hold important implications [phosphate, potassium, calcium], but they have no day to day implications... none whatsoever... for our physical or our experience of well-being."





Mean difference in rating between patients/caregivers and health professionals

**Ability to travel** Dialysis-free time Dialysis adequacy Washed out after dialysis Anemia Mobility **Blood** pressure Fatigue Impact on family/friends Pain Ability to work Potassium Infection/Immunity Target weight Cardiovascular disease Depression Vascular access problems Drop in blood pressure Hospitalization Death/mortality



# The SONG Initiative

To establish core outcomes for research (trials) across CKD

**Core outcome set:** an agreed standardised set of outcomes that should be measured and reported, as a minimum, in all clinical trials in specific areas of health.

 Included on the basis of importance (important to patients for decision-making) even if there is no difference



# The SONG Initiative

### To establish core outcomes for research (trials) across CKD



SONG-HD Haemodialysis



SONG-KIDS Children and adolescents



SONG-TX Kidney transplantation



SONG-PD Peritoneal dialysis



SONG-GD Glomerular disease



SONG-PKD Polycystic kidney disease



SONG-CKD Chronic kidney disease



GET INVOLVED



# The SONG Initiative

## To establish core outcomes for research (trials) across CKD



SONG-HD





Kidney transplantation



SONG-PD



SONG-GD



## More than 5000 patients/caregivers & 5000 health professionals 100 countries

SONG-PKD Polycystic kidney disease SONG-CKD

**GET INVOLVED** 

Each stream (HD, Tx, PD, PKD, Kids, GD, CKD) has involved n > 1000 from ~ 70 countries

## SONG-HD

Hemodialysis



#### **1 CORE OUTCOMES**

Critically important to all stakeholder groups Report in all trials

#### 2 MIDDLE TIER

Critically important to some stakeholder groups Report in some trials

#### **3 OUTER TIER**

Important to some or all stakeholder groups Consider for trials

# 2 Ability to travel Ability to work Ability to work Anemia Blood p Depres Dialy FATIGUE CARDIOVASCULAR DISEASE VASCULAR ACCESS MORTALITY

Anemia Blood pressure Depression Dialysis adequacy Dialysis-free time Drop in blood pressure Hospitalization Impact on family/ friends Infection/immunity Mobility Pain Potassium Target weight


Washed out after dialysis

3 Anxiety/stress Bone health Calcium Cognition Cramps Financial impact Food enjoyment Itching Nausea/vomiting Parathyroid hormone Phosphate Restless legs syndrome Sexual function Sleep

ge of Medicine blic Health

# Implementation


Funding agencies Trials Journals Regulators Guidelines NIHR, NIH SPIRIT, ISRCTN, AKTN CKT, NDT NHS, EMA, FDA, EMA/ESOT KDIGO, CARI (Cochrane)



## Next steps, some examples

- Systems dynamic model for care
- NIKKT transplantation for Aboriginal and/or Torres Strait Islander people
- SONG-Equity
- Patient navigators to improve access, care and outcomes
- Less frequent dialysis trial
- "Equity" lens across all research





# Outline





Evidence ecosystem in CKD



## **Opportunities and challenges**

